Is POLB or CIR more profitable?

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% Circassia Group N/A N/A N/A

Is POLB or TILS more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% Tiziana Life Sciences N/A N/A N/A

Does the media prefer POLB or TILS?

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Poolbeg Pharma. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 1 mentions for Poolbeg Pharma. Tiziana Life Sciences' average media sentiment score of 1.19 beat Poolbeg Pharma's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Poolbeg Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, POLB or VSN?

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Poolbeg Pharma N/A N/A -£4.50B -£0.94 N/A Verseon N/A N/A N/A -£14.30 N/A

Is POLB or VSN more profitable?

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% Verseon N/A N/A N/A

Is POLB or SCLP more profitable?

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% Scancell -116.98% 90.29% -45.28%

Poolbeg Pharma (POLB) Competitors

GBX 8.24 -0.12 (-1.44%)

As of 03:25 AM Eastern

Compare

POLB vs. ARIX, CIR, TILS, VSN, and SCLP

Should you buy Poolbeg Pharma stock or one of its competitors? Poolbeg Pharma's main competitors and comparable companies include Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), and Scancell (SCLP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Poolbeg Pharma (LON:POLB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.812, indicating that its share price is 81% more volatile than the broader market.

Arix Bioscience has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A

Arix Bioscience has a net margin of 105.64% compared to Poolbeg Pharma's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Poolbeg Pharma	N/A	-55.47%	-21.33%

In the previous week, Poolbeg Pharma had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Arix Bioscience. Arix Bioscience's average media sentiment score of 0.00 equaled Poolbeg Pharma'saverage media sentiment score.

Company	Overall Sentiment
Arix Bioscience	Neutral
Poolbeg Pharma	Neutral

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Arix Bioscience beats Poolbeg Pharma on 9 of the 11 factors compared between the two stocks.

How does Poolbeg Pharma compare to Circassia Group?

Poolbeg Pharma (LON:POLB) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
Circassia Group	N/A	N/A	N/A

Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

In the previous week, Poolbeg Pharma had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Circassia Group. Poolbeg Pharma's average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company	Overall Sentiment
Poolbeg Pharma	Neutral
Circassia Group	Neutral

Summary

Circassia Group beats Poolbeg Pharma on 5 of the 8 factors compared between the two stocks.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Poolbeg Pharma (LON:POLB) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Poolbeg Pharma. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 1 mentions for Poolbeg Pharma. Tiziana Life Sciences' average media sentiment score of 1.19 beat Poolbeg Pharma's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Poolbeg Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
Tiziana Life Sciences	N/A	N/A	N/A

Tiziana Life Sciences has lower revenue, but higher earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

Summary

Tiziana Life Sciences beats Poolbeg Pharma on 5 of the 9 factors compared between the two stocks.

How does Poolbeg Pharma compare to Verseon?

Poolbeg Pharma (LON:POLB) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
Verseon	N/A	N/A	N/A

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
Verseon	N/A	N/A	N/A	-£14.30	N/A

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Poolbeg Pharma had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Verseon. Poolbeg Pharma's average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company	Overall Sentiment
Poolbeg Pharma	Neutral
Verseon	Neutral

Summary

Poolbeg Pharma beats Verseon on 4 of the 7 factors compared between the two stocks.

How does Poolbeg Pharma compare to Scancell?

Poolbeg Pharma (LON:POLB) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Scancell has higher revenue and earnings than Poolbeg Pharma. Scancell is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
Scancell	£4.71M	20.91	-£6.75M	-£0.55	N/A

In the previous week, Poolbeg Pharma had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Scancell. Poolbeg Pharma's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
Poolbeg Pharma	Neutral
Scancell	Neutral

Poolbeg Pharma has a beta of 1.812, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Scancell has a beta of 0.687, suggesting that its share price is 31% less volatile than the broader market.

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Comparatively, 15.5% of Scancell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
Scancell	-116.98%	90.29%	-45.28%

Summary

Poolbeg Pharma beats Scancell on 6 of the 11 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POLB vs. The Competition

Export

Metric	Poolbeg Pharma	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£62.91M	£3.70B	£7.02B	£2.89B
Dividend Yield	N/A	3.76%	2.58%	6.09%
P/E Ratio	-8.77	9.09	269.20	368.29
Price / Sales	N/A	1,255.38	588.82	83,647.94
Price / Cash	2.11	44.95	28.89	27.89
Price / Book	0.00	17.66	11.27	7.22
Net Income	-£4.50B	-£13.25M	£3.45B	£5.89B
7 Day Performance	14.44%	3.11%	1.92%	1.29%
1 Month Performance	17.71%	-1.68%	-0.58%	2.22%
1 Year Performance	188.11%	61.75%	75.49%	73.69%

Poolbeg Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POLB Poolbeg Pharma	N/A	GBX 8.24 -1.4%	N/A	+230.0%	£62.91M	N/A	N/A	12
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Poolbeg Pharma (POLB) Competitors

POLB vs. ARIX, CIR, TILS, VSN, and SCLP

How does Poolbeg Pharma compare to Arix Bioscience?

Summary

How does Poolbeg Pharma compare to Circassia Group?

Summary

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Summary

How does Poolbeg Pharma compare to Verseon?

Summary

How does Poolbeg Pharma compare to Scancell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POLB vs. The Competition

Poolbeg Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Poolbeg Pharma (POLB) Competitors

POLB vs. ARIX, CIR, TILS, VSN, and SCLP

How does Poolbeg Pharma compare to Arix Bioscience?

Which has more risk & volatility, ARIX or POLB?

Which has higher valuation and earnings, ARIX or POLB?

Is ARIX or POLB more profitable?

Does the media refer more to ARIX or POLB?

Do insiders and institutionals have more ownership in ARIX or POLB?

Summary

How does Poolbeg Pharma compare to Circassia Group?

Do institutionals & insiders believe in POLB or CIR?

Is POLB or CIR more profitable?

Which has preferable earnings & valuation, POLB or CIR?

Does the media refer more to POLB or CIR?

Summary

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Do institutionals and insiders believe in POLB or TILS?

Does the media prefer POLB or TILS?

Is POLB or TILS more profitable?

Which has preferable valuation and earnings, POLB or TILS?

Summary

How does Poolbeg Pharma compare to Verseon?

Is POLB or VSN more profitable?

Which has preferable valuation and earnings, POLB or VSN?

Do insiders & institutionals have more ownership in POLB or VSN?

Does the media refer more to POLB or VSN?

Summary

How does Poolbeg Pharma compare to Scancell?

Which has higher valuation and earnings, POLB or SCLP?

Does the media prefer POLB or SCLP?

Which has more volatility and risk, POLB or SCLP?

Do institutionals and insiders hold more shares of POLB or SCLP?

Is POLB or SCLP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POLB vs. The Competition

Poolbeg Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools